ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1533

Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+ B Cells in Preclinical Models of Autoimmune Disease
Abstract Number: 2432

In Vitro and In Vivo Evidence of the Steroid-Sparing Potential of Afimetoran, an Equipotent Toll-Like Receptor 7/8 Dual Antagonist
Abstract Number: 1648

In Vitro Expansion of ACPA-positive B Cells from Rheumatoid Arthritis Patients and Effect of Small Molecule NF-κB Inhibitors on Differentiation and Survival of (Autoreactive) Memory B Cells into Plasma Cells
Abstract Number: 1732

In Vitro Screening of siRNAs Designed to Knockdown Interferon Beta as a Novel Therapeutic Approach for Treatment of Adult and Juvenile Dermatomyositis
Abstract Number: 0928

In Vitro Study of Fibroblast-Like Synoviocytes and Macrophages-Like Synoviocytes Isolated from Rheumatoid Arthritis, Psoriatic Arthritis Patients and Healthy Subjects
Abstract Number: 1799

In VitroEvidence for the Restoration of Glucocorticoid Sensitivity by Toll-Like Receptor 7 and 8 Inhibition in Systemic Lupus Erythematosus
Abstract Number: 2662

In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases
Abstract Number: 0718

Incidence and Patient Profile Changes in ANCA-Associated Vasculitis Following the SARS-CoV-2 Pandemic
Abstract Number: 1515

Incidence and Predictors of Neuropsychiatric Lupus—a Contemporary Cohort Study Across the United States
Abstract Number: 2372

Incidence and Predictors of Recurrent Pericarditis in Systemic Lupus Erythematosus
Abstract Number: 1455

Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients with Psoriatic Arthritis
Abstract Number: 0724

Incidence of ANCA-Associated Vasculitis in a Northern Spanish Health Region Between 2000-2023: A Populatio-based Study
Abstract Number: 0859

Incidence of Aortic Aneurysm, Dissection, or Rupture Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Abstract Number: 1505

Incidence of Cardiovascular and Venous Thromboembolic Events in Four Autoantibody-defined Systemic Lupus Erythematosus Clusters
Abstract Number: 2568

Incidence of First Fracture in RA Is Increasing Faster Than the General Population

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].